One page, thousands of outlets. See who else covered it.
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
We haven't written up this one. Decrypt has the full story — the link below goes straight to it.
The new FDA commissioner, a medical doctor and deputy director of the White House Domestic Policy Council, will have to balance a raft of competing priorities.
Matthew McClure, Goldman Sachs global co-head of investment, says the IPO market is "open for business," with AI-related companies accounting for more than half of capital raised despite representing…
Gold (XAU/USD) skyrockets on Wednesday as the Greenback edges lower amid falling US bond yields, driven by the US Treasury's buyback of long-dated bonds.
